Monopar Therapeutics (MNPR) Shares Outstanding (Weighted Average) (2016 - 2025)

Monopar Therapeutics has disclosed Shares Outstanding (Weighted Average) across 10 years of filings, most recently posting $7.4 million for Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $7.4 million, up 95.53% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.4 million (up 95.53% YoY), and the FY2025 annual result was $7.4 million, up 95.53% from the prior year.
• Shares Outstanding (Weighted Average) came in at $7.4 million for Q4 2025 at Monopar Therapeutics, up from $7.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $13.3 million in Q2 2023 to a low of $2.8 million in Q4 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $9.8 million (2021), against an average of $8.7 million.
• Across the five-year window, Shares Outstanding (Weighted Average) tumbled 78.26% in 2023 and surged 118.62% in 2025, its largest moves.
• Monopar Therapeutics' Shares Outstanding (Weighted Average) stood at $12.5 million in 2021, then rose by 1.97% to $12.7 million in 2022, then sank by 78.26% to $2.8 million in 2023, then jumped by 37.08% to $3.8 million in 2024, then surged by 95.53% to $7.4 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $7.4 million (Q4 2025), $7.1 million (Q3 2025), and $7.0 million (Q2 2025), per Business Quant data.